--Completed all merger and integration activities in Q2-- --Repaid $10 million of Senior Secured Notes ahead of schedule-- --Zyla products partially contributed to Q2 net product sales of $20.2 million -- --Combined second quarter 2020 net product sales of $27.7 million , on a pro forma basis,

LAKE FOREST, Ill. , July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020 financial results will be released on Friday, August 7, 2020 .

Trading under ASRT on Nasdaq Global Select Market Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million¹ Upwards of $40 million in Expected Cost Synergies LAKE FOREST, Ill. , May 20, 2020 /PRNewswire/ -- Assertio Holdings, Inc., the successor issuer to Assertio

-- Completed Strategic Asset Sales of NUCYNTA ® Franchise and Gralise ® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt -- -- Merger with Zyla Life Sciences On Track and Expected to Close Shortly After the Company’s 2020 Annual Meeting

 Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting Assertio Reaffirms its Ability to Achieve Upwards of $40 Million in Synergies Will Report First Quarter 2020 Financial Results on Monday, May 11, 2020 Prior to the Open of Markets LAKE FOREST, Ill.

LAKE FOREST, Ill. , April 08, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal

Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million , Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd

LAKE FOREST, Ill. , March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50%

  -- Reports Neurology Franchise Annual Net Sales of $108.1 Million , Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA ® Franchise and Gralise ®  Totaling $502.5 Million -- -- Repaid in Full Senior Secured Debt and Reduced Convertible Debt by $188.0 Million --

LAKE FOREST, Ill. , March 02, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced that it will release fourth quarter and full year 2019 financial results on Monday, March 9, 2020 , after the close of markets.